BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 31906998)

  • 1. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
    Schüttrumpf L; Marschner S; Scheu K; Hess J; Rietzler S; Walch A; Baumeister P; Kirchner T; Ganswindt U; Zitzelsberger H; Belka C; Maihoefer C
    Radiat Oncol; 2020 Jan; 15(1):7. PubMed ID: 31906998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
    Maihoefer C; Schüttrumpf L; Macht C; Pflugradt U; Hess J; Schneider L; Woischke C; Walch A; Baumeister P; Kirchner T; Zitzelsberger H; Belka C; Ganswindt U
    Radiat Oncol; 2018 Jul; 13(1):123. PubMed ID: 29970111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Maguire PD; Neal CR; Hardy SM; Schreiber AM
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
    Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
    Trials; 2014 Nov; 15():469. PubMed ID: 25432788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma.
    Saksø M; Andersen E; Bentzen J; Andersen M; Johansen J; Primdahl H; Overgaard J; Eriksen JG
    Acta Oncol; 2019 Oct; 58(10):1495-1501. PubMed ID: 31519130
    [No Abstract]   [Full Text] [Related]  

  • 7. Salvage surgery for advanced stage head and neck squamous cell carcinoma following radiotherapy or chemoradiation.
    Elbers JBW; Veldhuis LI; Bhairosing PA; Smeele LE; Jóźwiak K; van den Brekel MWM; Verheij M; Al-Mamgani A; Zuur CL
    Eur Arch Otorhinolaryngol; 2019 Mar; 276(3):647-655. PubMed ID: 30673847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
    Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Limaye S; Damjanov N; Di Stefano J; Ciunci C; Genden EM; Wisnivesky JP; Ferrandino R; Mamtani R; Langer CJ; Cohen RB; Sigel K
    J Natl Cancer Inst; 2019 May; 111(5):490-497. PubMed ID: 30239887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.
    Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z
    Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
    Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
    Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Adjuvant Therapy With Chemoradiation vs Radiation Alone for Patients With HPV-Negative N2a Head and Neck Cancer.
    Yan F; Li H; Kaczmar JM; Sharma AK; Day TA; Neskey DM; Pipkorn P; Zenga J; Graboyes EM
    JAMA Otolaryngol Head Neck Surg; 2020 Dec; 146(12):1109-1119. PubMed ID: 32790830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of salvage surgery for recurrent or residual head and neck squamous cell carcinoma.
    Maruo T; Zenda S; Shinozaki T; Tomioka T; Okano W; Sakuraba M; Tahara M; Hayashi R
    Jpn J Clin Oncol; 2020 Mar; 50(3):288-295. PubMed ID: 31845736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of adjuvant treatment and primary anatomical site in head and neck basaloid squamous cell carcinoma survival: an analysis of the National Cancer Database.
    Gootee J; Patel M; Aurit S; Silberstein P
    Clin Transl Oncol; 2020 Dec; 22(12):2264-2274. PubMed ID: 32440914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas.
    Bohlen M; Busch C-; Sehner S; Forterre F; Bier J; Berliner C; Bußmann L; Münscher A
    Eur Arch Otorhinolaryngol; 2019 Apr; 276(4):1183-1189. PubMed ID: 30725209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study.
    Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X
    Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node ratio as a prognostic factor in head and neck cancer patients.
    Chen CC; Lin JC; Chen KW
    Radiat Oncol; 2015 Aug; 10():181. PubMed ID: 26302761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated Radiotherapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancers: Evaluation of Response and Compliance.
    Mashhour K; Atef H; Selim A; A Moez M; Zawam H; Abo-Madyan Y
    Asian Pac J Cancer Prev; 2020 May; 21(5):1399-1407. PubMed ID: 32458648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.